{"url_path":"/sec/pmi/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 EXHIBIT AND FINANCIAL STATEMENT SCHEDULES**","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/2030617/0001437749-26-017171-index.html","accession_number":"0001437749-26-017171","cik":"0002030617","ticker":"PMI","issuer_name":"Picard Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2030617/0001437749-26-017171-index.html","primary_entity_key":"0002030617","primary_entity_name":"Picard Medical, Inc."},"word_count":273,"has_tables":true,"body_markdown":"**ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES**\n\n \n\n(a)\n\nDocuments filed as part of this Form 10-K/A.\n\n \n\nThe financial statements and required financial statement schedules are included in the Original Filing. \n\n \n\n(b)\n\nExhibits.\n\n \n\n31.1*\n\n[Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).](ex_963062.htm)\n\n31.2*\n\n[Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).](ex_963063.htm)\n\n32.1+\n\n[Certification of the Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.](http://www.sec.gov/Archives/edgar/data/0002030617/000143774926010133/ex_937869.htm\"%20\\t%20\"_blank)\n\n32.2+\n\n[Certification of the Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.](http://www.sec.gov/Archives/edgar/data/0002030617/000143774926010133/ex_937870.htm\"%20\\t%20\"_blank)\n\n101.INS*\n\nInline XBRL Instance Document (The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document)\n\n104\n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n*\n\nFiled herewith.\n\n+\n\nPreviously filed.\n\n \n\n \n\n \n\n \n\nTable of Contents\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\nPICARD MEDICAL, INC.\n\n \n \n \n\n \n\nBy\n\n/s/ Patrick NJ Schnegelsberg\n\n \n \n\nPatrick NJ Schnegelsberg\n\n \n \n\nChief Executive Officer\n\n \n \n \n\n \n\nDate:\n\n \n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company May 14, 2026 in the capacities indicated below.\n\n \n\n/s/ Patrick NJ Schnegelsberg\n\n \n \n\nPatrick NJ Schnegelsberg\n\nPrincipal Executive Officer and Director\n\n \n \n\n \n \n \n\n/s/ Bernard Skaggs\n\n \n \n\nBernard Skaggs\n\nPrincipal Financial Officer and Principal Accounting Officer\n\n \n \n\n \n \n \n\n/s/ Richard Fang\n\n \n \n\nRichard Fang\n\nDirector\n\n \n \n\n \n \n \n\n/s/ George Ye\n\n \n \n\nGeorge Ye\n\nDirector\n\n \n \n\n/s/ Sam Van\n\nSam Van\n\nDirector"}